NeoPrediX, an innovative leader in predictive analytics for neonatal, maternal, and perinatal health, has secured an investment from Springhood Ventures. This new round of funding will accelerate the development of state-of-the-art solutions aimed at enhancing newborn outcomes worldwide.
NeoPrediX develops proprietary algorithms to predict risks of neonatal, maternal, and perinatal health conditions, aiding clinical decision-making with its digital health solutions.
Springhood Ventures, a VC firm focused on children's health, supports early-stage companies improving health outcomes in early life. They back entrepreneurs advancing science and technology with strong commercial potential.
This partnership represents a major step forward in their joint mission to enhance neonatal health through innovative, evidence-based technology worldwide.
NeoPrediX participated in Venture Leaders Medtech in 2023.
Neopredix team
